Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

After metabolic bariatric surgery for obesity, 69.5 percent of patients demonstrated improvement or remission of psoriasis. HealthDay News — Metabolic bariatric surgery (MBS) is associated with ...

Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her symptoms, you know that the skin condition is far from glamorous and ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

For the 7.5 million Americans diagnosed with psoriasis, it can be disheartening to hear that there's no cure. But there are several treatments that can help keep this autoimmune disease under control.

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.